Can I Take St. John's Wort with Dayvigo (Lemborexant)?

Why This Combination Is Contraindicated

Lemborexant cannot maintain therapeutic blood concentrations when St. John's Wort is present. The FDA prescribing information for Dayvigo states explicitly that concomitant use with strong CYP3A4 inducers is contraindicated because the interaction reduces drug exposure to a degree that makes the medication clinically ineffective. [1]

St. John's Wort (Hypericum perforatum) contains hyperforin, the constituent primarily responsible for inducing cytochrome P450 3A4 and P-glycoprotein (P-gp). Lemborexant is a CYP3A4 substrate. When the enzyme is induced, it metabolizes lemborexant faster than the body can absorb it, collapsing the drug's area under the curve (AUC) and peak concentration (Cmax). The clinical result is a return of the insomnia the drug was prescribed to treat.

The CYP3A4 Pathway Explained

CYP3A4 is the most abundant drug-metabolizing enzyme in the human liver and intestinal wall, responsible for metabolizing roughly 50% of all clinically used medications. [2] Lemborexant is classified by the FDA as a sensitive CYP3A4 substrate, meaning its pharmacokinetics are strongly dependent on CYP3A4 activity. A strong inducer can reduce the AUC of a sensitive substrate by 80% or more in some cases.

Hyperforin in St. John's Wort activates the pregnane X receptor (PXR), a nuclear receptor that upregulates transcription of CYP3A4 and P-gp genes. [3] The induction is dose-dependent and preparation-dependent. Standardized extracts containing 3 to 5% hyperforin produce the strongest induction. Low-hyperforin preparations exist but are less common in the U.S. Market, and consumers rarely know which formulation they are taking.

How Induction Differs from Inhibition

Drug interactions are often confused. Inhibition (blocking the enzyme) raises drug levels, which risks toxicity. Induction (speeding up the enzyme) lowers drug levels, which risks treatment failure. For lemborexant with St. John's Wort, the danger is not sedation or overdose; it is that the medication stops working. A patient may conclude Dayvigo is ineffective and seek higher doses or additional sedatives, creating a secondary risk.

What the Pharmacokinetic Data Actually Show

The Dayvigo clinical pharmacology program included dedicated drug-drug interaction studies using probe CYP3A4 inducers and inhibitors. Rifampin, a prototypical strong CYP3A4 inducer, reduced lemborexant AUC by approximately 87% in healthy volunteers. [1] St. John's Wort is classified in the same inducer tier as rifampin for regulatory purposes, which is why the FDA label treats both as contraindicated co-administrations rather than dose-adjustment scenarios.

The FDA uses a geometric mean AUC ratio threshold of 0.50 (i.e., a 50% or greater reduction in exposure) to trigger a contraindication recommendation for narrow-therapeutic-window drugs or drugs with concentration-dependent efficacy. Lemborexant's therapeutic activity depends on sustained receptor occupancy at orexin OX1 and OX2 receptors; below a minimum plasma concentration, receptor occupancy falls below the threshold needed to suppress wake-promoting signaling. [4]

Lemborexant's Normal Pharmacokinetic Profile

Under standard conditions, lemborexant reaches peak plasma concentration (Tmax) at approximately 1 to 3 hours post-dose. Its terminal half-life is roughly 17 to 19 hours. [1] Protein binding exceeds 94%. The drug is largely eliminated via CYP3A4-mediated hepatic metabolism, with less than 1% excreted unchanged in urine.

When CYP3A4 is strongly induced, both the Tmax concentration and the duration of therapeutic exposure shrink. The drug may still reach a detectable plasma level, but the exposure is insufficient to support the 7 to 8 hours of sleep-promoting receptor blockade that the 5 mg or 10 mg doses are calibrated to deliver.

Why "Low-Dose" St. John's Wort Is Not a Safe Workaround

Some patients reason that taking a lower dose of St. John's Wort will sidestep the interaction. The research does not support this. A 2003 clinical pharmacology study by Wang et al. Demonstrated that even 300 mg three times daily of a low-hyperforin St. John's Wort extract produced measurable CYP3A4 induction, and standard-hyperforin products at the same dose caused substantially greater induction. [3] Because lemborexant is a sensitive substrate, even moderate induction may push its exposure below the clinical threshold.

The Time Course of the Interaction

Understanding when the interaction starts and stops is essential for safe management.

Onset of Induction

CYP3A4 induction is not immediate. Hyperforin must accumulate in tissue, activate PXR, upregulate gene transcription, and allow new enzyme protein to be synthesized. This process takes approximately 7 to 14 days of regular St. John's Wort use before maximal induction is achieved. [5] A single accidental dose is unlikely to produce clinically significant lowering of lemborexant levels, but regular daily use will.

Reversal After Stopping St. John's Wort

Once St. John's Wort is discontinued, CYP3A4 induction reverses as the surplus enzyme protein is degraded and replaced at baseline rates. Full reversal typically takes 2 to 4 weeks. [5] During that window, lemborexant levels may still be lower than expected, though the magnitude of the interaction will decrease progressively each week.

A prescriber adjusting a patient's regimen should account for this washout period. Restarting lemborexant at a standard dose the day after stopping St. John's Wort may still yield subtherapeutic concentrations for one to two weeks.

Clinical Context: Who Is Most at Risk?

Not every patient taking both agents experiences the same degree of risk. The following framework helps clinicians and patients assess individual vulnerability.

High-risk profile:

• Taking standardized St. John's Wort extract (standardized to 0.3% hypericin or 3 to 5% hyperforin)
• Using St. John's Wort daily for more than 2 weeks
• Prescribed lemborexant 5 mg (the lower dose has less pharmacokinetic buffer than 10 mg)
• Reporting treatment failure on lemborexant without a clear reason

Moderate-risk profile:

• Using a non-standardized or low-hyperforin St. John's Wort product intermittently
• Using St. John's Wort for fewer than 7 days
• Currently on lemborexant 10 mg with partial but not complete loss of sleep benefit

Lowest-risk scenario (still not recommended):

• Single accidental dose of St. John's Wort
• Lemborexant not yet initiated (can sequence the agents safely by allowing full washout)

The core clinical message: there is no established dose-separation window (taking the two agents at different times of day) that neutralizes the interaction. Enzyme induction is systemic and persistent, not time-of-dose dependent.

Other CYP3A4 Inducers to Watch

St. John's Wort is not the only supplement or drug that triggers this interaction. Recognizing the broader class helps patients avoid substituting one problematic agent for another.

Prescription Inducers Contraindicated with Lemborexant

The FDA label lists the following as contraindicated due to strong CYP3A4 induction: rifampin, carbamazepine, phenytoin, and St. John's Wort. [1] Moderate inducers such as efavirenz, bosentan, and nafcillin call for a dose increase of lemborexant to 10 mg if clinically appropriate, per the label.

Other Herbal Products with Induction Potential

Several other commonly used herbal supplements have demonstrated CYP3A4 induction activity in vitro or in preliminary clinical studies, including valerian root (weak, evidence limited) and echinacea (moderate, preparation-dependent). [6] None are as well-characterized or as potent as St. John's Wort, but patients should disclose all supplements to their prescriber.

What to Do If You Are Already Taking Both

Discovering you have been taking both is stressful. The steps below are not a substitute for speaking with your prescriber, but they provide a clinical framework for understanding your options.

Step 1: Do Not Abruptly Stop Lemborexant Without Guidance

Lemborexant does not carry the physiologic dependence risk of benzodiazepines, but abrupt discontinuation in a patient with chronic insomnia can still lead to rebound insomnia. A prescriber should guide the transition.

Step 2: Taper or Discontinue St. John's Wort

If the goal is to restore lemborexant efficacy, St. John's Wort should be stopped. Because St. John's Wort is used for mild-to-moderate depression in some patients, that underlying condition needs an alternative management plan. The American College of Physicians 2023 clinical practice guideline on adult depression management recommends evidence-based options including cognitive behavioral therapy and first-line antidepressants as alternatives. [7]

Step 3: Allow a Washout Period

Wait 2 to 4 weeks after stopping St. John's Wort before expecting lemborexant to perform at full therapeutic capacity. Sleep diaries during this period help document whether efficacy is returning.

Step 4: Consider Switching Sleep Aids

If St. John's Wort cannot be stopped (patient preference, cost of alternatives, partial antidepressant benefit), a different hypnotic that does not rely on CYP3A4 metabolism may be appropriate. Doxepin 3 to 6 mg, for example, is metabolized primarily via CYP2D6 and CYP1A2 and would not share this specific interaction. [8] That is a prescriber decision requiring a full medication review.

Understanding St. John's Wort: Why Patients Use It

St. John's Wort is the most widely used herbal antidepressant in the world. A 2018 National Center for Complementary and Integrative Health (NCCIH) survey found that approximately 3% of U.S. Adults had used it in the prior 12 months. [9] Common reasons include mild depression, anxiety, and, importantly, sleep problems.

The irony for patients combining it with Dayvigo is that St. John's Wort is sometimes taken specifically to support better sleep, since its mild serotonergic and melatoninergic activity may improve mood-related insomnia at low doses. But the CYP3A4 induction effect of hyperforin simultaneously sabotages the prescription sleep aid meant to address the same symptom.

Evidence for St. John's Wort in Depression

The Cochrane systematic review by Linde et al. (N=5,489, 29 trials) found St. John's Wort extracts superior to placebo for mild-to-moderate depression and roughly equivalent in efficacy to standard antidepressants, with a more favorable adverse-effect profile. [10] This is the strongest evidence base for its use. Evidence specifically for insomnia as a primary indication remains limited to small trials and is not sufficient to support its use as a standalone hypnotic.

Drug Interaction Burden of St. John's Wort

St. John's Wort has the broadest documented drug interaction profile of any common supplement. Documented clinically significant interactions include cyclosporine (organ transplant rejection documented), HIV antiretrovirals including indinavir, oral contraceptives, warfarin, digoxin, and multiple antidepressants via pharmacodynamic serotonin syndrome risk. [3] The prescribing information for dozens of medications now carries explicit warnings. For a patient managing insomnia with a prescription sleep aid, this is a high-risk supplement to add without disclosure.

How Lemborexant Works (and Why Enzyme Induction Undermines It)

Lemborexant is a dual orexin receptor antagonist (DORA). It competitively blocks orexin OX1 and OX2 receptors in the brain. Orexin (also called hypocretin) is the primary wake-promoting neuropeptide. Blocking its receptors reduces wake drive without globally suppressing the CNS, which is the mechanistic difference between DORAs and older sedative-hypnotics. [4]

The SUNRISE-2 trial (N=949), the key phase 3 study supporting Dayvigo's FDA approval, showed lemborexant 5 mg and 10 mg both produced statistically significant improvements in sleep onset and sleep maintenance versus placebo at 12 months. Specifically, subjective sleep onset latency decreased by 19.5 minutes with lemborexant 10 mg versus 9.4 minutes with placebo (P<0.0001). [11] Those clinical gains depend entirely on the drug reaching adequate plasma concentrations to maintain receptor blockade through the night. Enzyme induction eliminates that concentration.

The Receptor Occupancy Threshold

Preclinical receptor binding data and clinical PK/PD modeling for lemborexant suggest that sleep maintenance requires sustained plasma concentrations above a minimum threshold that occupies both OX1 and OX2 receptors sufficiently to dampen, though not abolish, orexin signaling. When CYP3A4 induction shortens the drug's effective half-life and compresses its AUC, plasma levels may dip below this threshold during the second half of the night, producing early-morning awakening even when sleep onset initially improves.

Counseling Points for Patients

Patients often assume that because St. John's Wort is "natural," it cannot interfere with medications. That assumption is clinically dangerous in this context. Several direct counseling points are worth emphasizing.

First, "natural" does not mean pharmacologically inert. Hyperforin is a potent ligand for a nuclear receptor that controls dozens of drug-metabolizing genes.

Second, the interaction is silent. There is no symptom that signals low lemborexant levels other than the return of insomnia, which a patient may attribute to the drug "wearing off" rather than to a supplement interaction.

Third, disclosing all supplements to a prescriber is not optional for patients on Dayvigo. The Dayvigo prescribing information and FDA drug-drug interaction guidance both require prescribers to ask about CYP3A4 inducer use before initiating therapy. [1]

The American Society of Health-System Pharmacists (ASHP) guidelines on drug-supplement interactions state: "Clinicians should routinely query patients about use of herbal and botanical products using open-ended, non-judgmental questioning, as patients frequently do not volunteer this information." [12]

Fourth, if a patient is using St. John's Wort for depression and feels it is helping, the correct step is not to quietly continue both. A clinician can find a non-CYP3A4-affecting alternative or transition the patient to a pharmacologically compatible sleep aid.

Prescriber Checklist Before Starting Lemborexant

Before prescribing Dayvigo at any dose, the following should be confirmed:

• Patient is not taking rifampin, carbamazepine, phenytoin, or phenobarbital
• Patient is not taking St. John's Wort in any form or dose
• Patient is not on a moderate inducer without a plan to use the 10 mg dose
• Complete medication list including OTC supplements has been reviewed
• Patient has been counseled to check with the prescribing team before adding any new supplement

The FDA Dayvigo full prescribing information (Section 7.1, Drug Interactions) lists this requirement explicitly. [1] Documenting that the conversation occurred is standard of care for any drug with a narrow concentration-dependent therapeutic window.